Q32 Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	53.74	-	-6.65	3.21	33.97
Revenue Growth (YoY)	-	-	-	-	-90.56%	1157.25%
Gross Profit	-	53.74	-	-6.65	3.21	33.97
Selling, General & Admin	17.08	17.68	17.96	9.88	38.14	36.84
Research & Development	15.25	19.16	48.14	31.73	98.35	93.09
Total Operating Expenses	32.33	36.84	66.1	41.6	136.49	129.92
Operating Income	21.41	16.9	-66.1	-48.26	-133.28	-95.95
Other Non-Operating Income (Expense)	-	11.74	-	-	-	-
Total Non-Operating Income (Expense)	11.83	12.92	20.02	-5.17	134.48	0.19
Pretax Income	33.24	29.82	-46.09	-53.43	1.2	-95.76
Provision for Income Taxes	-	-	0.02	0.32	0.72	-
Net Income	33.24	29.82	-46.11	-53.74	0.48	-95.76
Net Income to Common	40.85	29.82	-47.73	-53.74	-5.01	-95.76
Shares Outstanding (Basic)	13	12	9	3	3	3
Shares Outstanding (Diluted)	13	12	10	3	3	3
Shares Change (YoY)	5.59%	27.51%	214.45%	-	-	20.41%
EPS (Basic)	2.68	2.42	-5.12	-153.96	-6.09	-31.14
EPS (Diluted)	2.66	2.42	-6.58	-153.96	-6.09	-31.14
Free Cash Flow	-27.4	-33.54	-67.79	-18.68	-114.95	-112.15
Free Cash Flow Per Share	-2.14	-2.72	-7.02	-6.08	-37.43	-36.51
Gross Margin	-	100.00%	-	100.00%	100.00%	100.00%
Operating Margin	-	31.45%	-	725.53%	-4154.64%	-282.44%
Profit Margin	-	55.49%	-	808.04%	15.06%	-281.90%
FCF Margin	-	-62.42%	-	280.89%	-3583.10%	-330.13%
EBITDA	21.77	17.29	-65.62	-47.76	-131.99	-87.6
EBITDA Margin	-	32.18%	-	718.03%	-4114.34%	-257.86%
EBIT	21.41	16.9	-66.1	-48.26	-133.28	-95.95
EBIT Margin	-	31.45%	-	725.53%	-4154.64%	-282.44%
Effective Tax Rate	-	0.00%	-0.05%	-0.60%	59.68%	0.00%

SEC Filings: 10-K · 10-Q